This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mo, Y. Articles by Au, J. L-S. Search for Related Content PubMed PubMed Citation Articles by Mo, Y. Articles by Au, J. L-S.

Simultaneous Targeting of Telomeres and Telomerase as a Cancer Therapeutic Approach¹

College of Pharmacy [Y. M., Y. G., S. S., J. J., X. X., M. G. W., J. L-S. A.], and James Cancer Hospital and Solove Research Institute [M. G. W., J. L-S. A.], The Ohio State University, Columbus, Ohio 43210

Telomeres, which are important for maintaining chromosome integrity and functions, shorten with each cell division. Telomerase, responsible for telomere synthesis, is expressed in 90% of human tumor cells but seldom in normal somatic cells. This study evaluated the hypothesis that simultaneous shortening of telomeres and inhibition of telomerase results in synergistic and tumor-selective cytotoxicity. In telomerase-positive human pharynx FaDu tumor cells, paclitaxel caused telomere erosion (first detected at 1 h) and apoptosis. Expression of antisense to the RNA component of human telomerase (hTR) inhibited telomerase activity, shortened telomere length, reduced cell growth rate, and resulted in a significant higher sensitivity to paclitaxel. Another telomerase inhibitor, 3'-azido-3'-deoxythymidine (AZT), at a concentration that produced little or no cell detachment or apoptosis, inhibited the telomerase activity and enhanced the paclitaxel-induced cell detachment and apoptosis. AZT also enhanced the activity of paclitaxel in mice bearing well-established s.c. FaDu xenograft tumors (i.e., reduced residual tumor size, enhanced apoptotic cell fraction, and prolonged survival time), without enhancing host toxicity. In contrast, AZT did not enhance the paclitaxel activity in the telomerase-negative osteosarcoma Saos-2 cells nor in FaDu cells where telomerase was already suppressed by antisense hTR, confirming that the AZT effect in parent FaDu cells is mediated through telomerase inhibition. These results demonstrate that combined use of agents targeting both telomere and telomerase yielded synergistic activity selective for tumors that depend on telomerase for telomere maintenance.

This article has been cited by other articles:

				E. M. Goldblatt, E. R. Gentry, M. J. Fox, S. M. Gryaznov, C. Shen, and B.-S. Herbert The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel Mol. Cancer Ther., July 1, 2009; 8(7): 2027 - 2035. [Abstract] [Full Text] [PDF]

				Y. Jin, Y. Stewenius, D. Lindgren, A. Frigyesi, O. Calcagnile, T. Jonson, A. Edqvist, N. Larsson, L. M. Lundberg, G. Chebil, et al. Distinct Mitotic Segregation Errors Mediate Chromosomal Instability in Aggressive Urothelial Cancers Clin. Cancer Res., March 15, 2007; 13(6): 1703 - 1712. [Abstract] [Full Text] [PDF]

				T. Liu, B. Hu, M. J. Chung, M. Ullenbruch, H. Jin, and S. H. Phan Telomerase Regulation of Myofibroblast Differentiation Am. J. Respir. Cell Mol. Biol., May 1, 2006; 34(5): 625 - 633. [Abstract] [Full Text] [PDF]

				A. M. Burger, F. Dai, C. M. Schultes, A. P. Reszka, M. J. Moore, J. A. Double, and S. Neidle The G-Quadruplex-Interactive Molecule BRACO-19 Inhibits Tumor Growth, Consistent with Telomere Targeting and Interference with Telomerase Function Cancer Res., February 15, 2005; 65(4): 1489 - 1496. [Abstract] [Full Text] [PDF]

				T. Kondo, N. Oue, K. Yoshida, Y. Mitani, K. Naka, H. Nakayama, and W. Yasui Expression of POT1 is Associated with Tumor Stage and Telomere Length in Gastric Carcinoma Cancer Res., January 15, 2004; 64(2): 523 - 529. [Abstract] [Full Text] [PDF]

				E. S. Wang, K. Wu, A. C. Chin, S. Chen-Kiang, K. Pongracz, S. Gryaznov, and M. A. S. Moore Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma Blood, January 1, 2004; 103(1): 258 - 266. [Abstract] [Full Text] [PDF]

				N. A. Lanson Jr., P. L. Friedlander, P. Schwarzenberger, J. K. Kolls, and G. Wang Replication of an Adenoviral Vector Controlled by the Human Telomerase Reverse Transcriptase Promoter Causes Tumor-Selective Tumor Lysis Cancer Res., November 15, 2003; 63(22): 7936 - 7941. [Abstract] [Full Text] [PDF]

				Z. Chen, K. S. Koeneman, and D. R. Corey Consequences of Telomerase Inhibition and Combination Treatments for the Proliferation of Cancer Cells Cancer Res., September 15, 2003; 63(18): 5917 - 5925. [Abstract] [Full Text] [PDF]